# Patent

## Title
Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same

## Abstract

To identify a domain in HIF-1α protein, which participates in stabilization of a fused protein, DNA encoding the following polypeptide (A) or (B) is provided:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1, and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a nuclear localization signal and the other protein to form the fused protein.

## Background
RELATED APPLICATIONS
This application is U.S. National Phase of International Application PCT/JP2002/005482, filed Jun. 4, 2002 designating the U.S., and published in English as WO 2002/099104 on Dec. 12, 2002, which claims priority to Japanese Patent Application No. 2001-169948, filed Jun. 5, 2001 and Japanese Patent Application No. 2001-169949, filed Jun. 5, 2001.
TECHNICAL FIELD
The present invention relates to a polypeptide for unstabilizing a protein in a cell under aerobic conditions, DNA encoding the polypeptide and a method using the DNA. The present invention also relates to a vector, which comprises the DNA and is capable of expressing a fused protein having stability dependent on oxygen conditions in a cell.
Further, the present invention relates to a fused protein containing the above polypeptide and having protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell and a method of using the fused protein. The present invention also relates to a vector capable of expressing the fused protein.
The present invention is useful in the fields of the microbiological industry, medicinal drugs, medical care, and, the like.
BACKGROUND ART
The partial pressure of oxygen in a solid tumor is not uniform, and tumor cells are exposed to various oxygen environments. This results from the fact that the scattering distance of oxygen molecules from a blood vessel to the tissue of a tumor is limited. In the field of radiobiology, the inside of a solid tumor is divided into three regions, that is, 1) an aerobic region, 2) a dead region and 3) an hypoxic region according to the amount of oxygen supplied to each tumor cell.
1) Since an extremely large number of oxygen molecules are supplied to each tumor cell at a distance from a capillary vessel of up to 70 μm, this region is called “an aerobic region”. Oxygen molecules are indispensable for the acquisition of the effect of radiotherapy for solid tumors. Therefore, it is known that the aerobic region rich in oxygen molecules literally is a region having extremely high radiation sensitivity. The treatment effect of chemotherapy for the aerobic region is considered to be high because an anti-cancer drug is easily scattered from a blood vessel system to the aerobic region when chemotherapy is performed.
2) Oxygen molecules released from the blood vessel are consumed by tumor cells in the aerobic region while the molecules are scattered. Therefore, oxygen molecules required for survival of tumor cells existent in a region far from the capillary vessel are not supplied to the cells. As a result, tumor cells far from the blood vessel system at a distance of 70 μm or more die, thereby forming a dead region.
3) A hypoxic region composed of hypoxic cells is existent between the aerobic region and the dead region. The minimum amount of oxygen molecules required for the survival of tumor cells is supplied to the hypoxic region. However, oxygen molecules enough to obtain the effect of radiotherapy are not supplied. Therefore, the hypoxic region in the tumor has extremely low radiation sensitivity, which is considered to be one of the causes of the re-proliferation of tumor cells after the end of radiotherapy. Since the amount of an anti-cancer drug scattered from the blood vessel system to the hypoxic region is limited when a chemical treatment is performed, a satisfactory treatment effect cannot be expected in fact.
It has been difficult to confirm the existence of such a hypoxic cell. This is because there has been substantially no means of monitoring the existence of oxygen in a cell. Known as means of monitoring the hypoxic cells are a method of measuring an oxygen voltage of a cell using micro-electrodes, immunocytostaining using Pimonidazole (Hypoxyprobe-1) known as a hypoxic cell indicator, immunocytostaining using a gene product whose expression is induced in a cell under hypoxic conditions as a label, and the like. However, the above methods are technically difficult, and at present, also apparatuses for carrying out these are complex and not generally used. That is, the development of general-purpose means of detecting hypoxic cells has been desired.
As described above, in cancer treatment, the existence of hypoxic cancer cells hinders the treatment by radiotherapy or chemotherapy drug. Means of removing these cells effectively has been desired. Although only the use of a combination of a hypoxic cell radiation sensitizer and radiotherapy has been known to cope with the hypoxic cells, only one drug is now in a clinical trial stage and there does not currently exist a hypoxic cell radiation sensitizer which has been put to practical use. This results from the fact that 2-nitroimidazole which is the mother nucleus of the hypoxic cell radiation sensitizer is neurotoxic and it is difficult to control its toxicity and medical effect. That is, the development of means of getting rid of a hypoxic cancer cell effectively has been desired.
By the way, the expression of physiologically important genes such as a vascular endothelial growth factor (VEGF) and erythropoietin (EPO) is induced in a cell under a hypoxic environment. The expression of these genes is induced by hypoxia-inducible factor-1 complex (hereinafter, referred to as HIF-1) in a transfer level.
HIF-1 is a heterodimer consisting of HIF-1α protein and HIF-1β protein. These sub-units each have a domain for binding to DNA called “basic-helix-loop-helix domain (bHLH domain)” and a domain for forming a heterodimer called “PER-aryl hydrocarbon nuclear translocator (ARNT)-SIM (PAS) domain” at N termini. It has been found that the HIF-1α protein has two transactivation domains, that is, N- and C-transactivation domains (N-TAD, C-TAD).
The activation mechanism dependent on the oxygen concentration of HIF-1 has recently been clarified. The transfer and translation of HIF-1β mRNA are always activated and its gene product (protein) is always expressed non-dependent on the partial pressure of oxygen in the outside world. Although the transfer and translation of HIF-1α mRNA are also always activated, the biosynthesized HIF-1α protein is positively degraded under aerobic conditions and is existent stably only under hypoxic conditions.
It has thus been found that the stability of the HIF-1α protein is controlled dependent on the concentration of oxygen in the outside world and that the transfer activity of HIF-1 is controlled dependent mainly on the amount of the protein.
To date, it has been reported that the 401a.a.-603a.a. domain is important for the stabilization of HIF-1α under hypoxic conditions in experiments using a partially deleted mutant of HIF-1α (Huang L E, Gu J, Schau M and Bunn H F. 1998. Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2-dependent degradation domain via. the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95:7987-7992: document 1). This domain is called “an Oxygen Dependent Degradation domain” (ODD domain).
It has been known that the oxygen dependent stability of HIF-1α suggests that amino acid residues in this domain be modified dependent on oxygen under aerobic conditions, be ubiquitinated in the end, and be degraded by proteasome (Huang, L. E., Gu, J. Schau, M. and Bunn, H. F. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA. 95: 7987-7992, 1998).
Therefore, it has also been known that HIF-1α can obtain the same stability as that under hypoxic conditions by culturing HIF-1α in a medium containing a proteasome inhibitor such as N-carbobenzoxyl-L-leucinyl-L-leucinyl-L-norvalinal (to be abbreviated as “Cbz-LLL” hereinafter) (Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D. and Goldberg, A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771, 1994: document 3). And this is disclosed (Sutter, C. H., Laughner, E. and Semenza, G. L. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc. Natl. Acad. Sci. USA. 97: 4748-4753, 2000: document 4). Through this fact, it has been assumed that the degradation of a fused protein containing the polypeptide is carried out through a degradation mechanism by ubiquitin-proteasome like HIF-1α and that the fused protein is stabilized under hypoxic conditions and in a medium containing Cbz-LLL.
It has been reported that the Gal-4 protein fused with 530a.a.-652a.a. of the HIF-1α protein is controlled to be positively degraded in a cultured cell only when the concentration of oxygen is high (Vickram Srinivas, Li-Ping Zhang, Xiao-Hong Zhu and Jaime Caro. 1999. Characterization of an Oxygen/Redox-Dependent Degradation Domain of Hypoxia-Inducible Factora (HIFα) Proteins. Biochem. Biophy. Res. Com. 260: 557-561: document 5). It has also been reported that when HIF-1α561a.a.-568a.a. in a gene fused with Gal-4 and 529a.a-826a.a. of HIF-1α is substituted by the alanine residue, the above control is lost. It is presumed, from this fact, that the domain around 561a.a.-568a.a. of HIF-1α where the HIF-1α of a mouse and human HIF-1α are well kept takes part in the oxygen concentration dependent stabilization of a protein. It is also discussed whether the 557a.a.-571a.a. domain of HIF-1α plays an important role in the control of the stability of the HIF-1α protein (above document 5).
However, the inventors of the present invention have found it impossible to make the stabilization of a fused protein dependent on the concentration of oxygen only with the 557a.a.-571a.a. domain. It cannot be said that the domain taking part in the stabilization of a fused protein of the HIF-1α protein is identified.
It was reported in 1988 that a protein called “TAT” derived from a human immunodeficiency virus (HIV) has the activity of transducing a protein through cell membrane (Cell; 55, 1179 (1988), Proc. Natl. Acad. Sci. USA; 91, 664 (1994)). After that, it was elucidated that a domain consisting of only 11 amino acids of TAT protein (TAT protein transduction domain) has the above activity. At the same time, it was also reported that β-galactosidase protein fused with this TAT protein transduction domain is introduced into a cell.
However, the relationship between the above HIF-1α and TAT and the relationship between HIF-1α and a protein having protein transduction activity through membrane have been unknown so far. Therefore, it has been unknown that when the HIF-1α protein having a specific region for controlling the stabilization of the HIF-1α protein, a protein having protein transduction activity through membrane and other protein are fused together, making use of the specific region, the obtained fused protein can be introduced into a cell and that in the cell harboring the fused protein, oxygen-dependent stability can be imparted to the fused protein.
DISCLOSURE OF THE INVENTION
The present invention has been made under the above situation, and it is an object of the present invention to identify a region of HIF-1α protein which can control the stability of any protein depending on the concentration of oxygen by fusing the protein and to control the expression of a specific gene and the expression of a fused protein corresponding to the gene according to the amount of oxygen by making use of the region.
It is another object of the present invention to provide a fused protein which comprises a protein having a region taking part in the stabilization of specified HIF-1α protein and has protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell and a method of controlling a fused protein, the method allowing the fused protein to be introduced into a cell advantageously and the stability of the fused protein to be adjusted according to the amount of oxygen in the fused protein-introduced cell.
It is still another object of the present invention to provide a vector capable of expressing the fused proteins.
The inventors of the present invention have conducted intensive studies to attain the above objects and have found that a region having the amino acid sequence of SEQ ID NO: 1 of the amino acid sequences of HIF-1α protein is a key part of a signal when a protein fused with the above region is degraded under aerobic conditions.
The inventors have also found that a fused protein containing HIF-1α protein having the above specific region and a protein having protein transduction activity through membrane is advantageously introduced into a cell. The present invention has been accomplished based on those findings.
That is, the present invention is as follows.
(1) A DNA encoding a polypeptide (A) or (B):
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1, and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a nuclear localization signal and the other protein to form the fused protein.
(2) The DNA according to (1), wherein the fused protein is stabilized to a larger extent in a cell under hypoxic conditions than under aerobic conditions.
(3) The DNA according to (1) or (2) which has the nucleotide sequence of SEQ ID NO: 2 or part thereof.
(4) A vector which comprises a DNA encoding a nuclear localization signal and a DNA encoding a polypeptide according to any one of (1) to (3), and which is capable of expressing a fused protein comprising the nuclear localization signal, the polypeptide, and other protein when a DNA encoding the other protein is inserted into these DNAs.
(5) The vector according to (4) which comprises the DNA encoding the other protein.
(6) The vector according to (5) which can unstabilize the fused protein in a cell harboring the vector under aerobic conditions.
(7) The vector according to (6), wherein the other protein is a labeling protein and/or a protein having cytotoxicity.
(8) A cell into which the vector according to any one of (4) to (7) is introduced.
(9) The cell according to (8) which is a cell of a microorganism.
(10) The microorganism according to (9) which is Escherichia coli. 
(11) A method of detecting a cell under hypoxic conditions, comprising: monitoring an existence state of the other protein which is a labeling protein in a cell harboring the vector according to (7).
(12) A method of controlling the existence of a protein in a cell, comprising: introducing the vector according to (6) into the cell; and expressing a fused protein to be encoded by the vector.
(13) A method of controlling the existence of a protein in a cell harboring a DNA encoding the protein, comprising: connecting the DNA encoding a nuclear localization signal and the DNA according to (1) to the DNA; and expressing a fused protein containing the nuclear localization signal, a polypeptide to be encoded by the DNA according to (1), and the protein.
(14) The method according to (13), wherein the fused protein is controlled to be existent in a cell under hypoxic conditions and not to be existent under aerobic conditions.
(15) A method of inhibiting growth of a cell under hypoxic conditions, comprising: allowing the cell to harbor the vector according to (7) in which the other protein is a protein having cytotoxicity so that the fused protein encoded by the vector exists in the cell under hypoxic conditions.
(16) A fused protein comprising a nuclear localization signal, a protein having protein transduction activity through membrane, a polypeptide (A) or (B), and other protein, the fused protein having protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1 and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a nuclear localization signal and the other protein to form the fused protein.
(17) The fused protein according to (16), wherein the protein having protein transduction activity through membrane is a protein (C) or (D) having a TAT signal sequence (TAT) derived from HIV:
(C) a protein having the amino acid sequence of SEQ ID NO: 4
(D) a protein having an amino acid sequence comprising at least 9 amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through membrane to the fused protein.
(18) A fused protein comprising a polypeptide (A) or (B1), a protein (C) or (D) having a TAT signal sequence (TAT) derived from HIV, and other protein, the fused protein having protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B1) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1, and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a TAT protein and the other protein to form the fused protein

(C) a protein having the amino acid sequence of SEQ ID NO: 4

(D) a protein having an amino acid sequence comprising at least 9 amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through membrane to a fused protein.

(19) The fused protein according to any one of (16) to (18), which exists more stably in a cell under hypoxic conditions than under aerobic conditions.
(20) The fused protein according to any one of (16) to (19), wherein the other protein is a labeling protein and/or a protein having cytotoxicity.
(21) A method of controlling the existence of a fused protein, comprising: allowing the fused protein according to (16) or (18) to be transduced into a cell from the outside of the cell; and controlling stability of the fused protein according to oxygen conditions in the transduced cell.
(22) The method of controlling the existence of a fused protein according to (21), wherein the fused protein is made existent more stably in a cell under hypoxic conditions than under aerobic conditions.
(23) A vector which comprises a DNA encoding a nuclear localization signal, a DNA encoding a protein having protein transduction activity through membrane, and a DNA encoding a polypeptide (A) or (B), and which is capable of expressing a fused protein comprising the nuclear localization signal, the protein having protein transduction activity through membrane, the polypeptide, and other protein when a DNA encoding the other protein is inserted into these DNAs:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1 and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a nuclear localization signal and the other protein to form the fused protein.
(24) The vector according to (23), wherein the protein having protein transduction activity through membrane is a protein (C) or (D) having a TAT signal sequence (TAT) derived from HIV:
(C) a protein having the amino acid sequence of SEQ ID NO: 4
(D) a protein having an amino acid sequence comprising at least 9 amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through membrane to the fused protein.
(25) A vector which comprises a DNA encoding a polypeptide (A) or (B1) and a DNA encoding a protein (C) or (D) having a TAT signal sequence (TAT) derived from: HIV and which is capable of expressing a fused protein comprising a TAT protein, the polypeptide, and other protein when a DNA encoding the other protein is inserted into these DNAs:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B1) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1, and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a TAT protein and the other protein to form the fused protein

(C) a protein having the amino acid sequence of SEQ ID NO: 4

(D) a protein having an amino acid sequence comprising at least 9 amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through membrane to the fused protein.

(26) The vector according to any one of (23) to (25), wherein the fused protein exists more stably in a cell under hypoxic conditions than under aerobic conditions.
(27) The vector according to any one of (23) to (25), wherein the DNA encoding a polypeptide has the nucleotide sequence of SEQ ID NO: 2 or part thereof.
(28) The vector according to any one of (23) to (25), wherein the DNA encoding a TAT protein has the nucleotide sequence of SEQ ID NO: 5 or part thereof.
(29) The vector according to any one of (23) to (28) which comprises the DNA encoding the other protein.
(30) The vector according to (29), wherein the other protein is a labeling protein and/or a protein having cytotoxicity.
The present invention will be detailed hereinbelow.
DNA which is a first aspect of the present invention is DNA encoding a polypeptide having the amino acid sequence of SEQ ID NO: 1. When the polypeptide is fused with a nuclear localization signal (to be abbreviated as NLS hereinafter) and another protein, the polypeptide provides stability dependent on an oxygen concentration to the other protein in a cell harboring the fused protein.
The above fused protein is held more stably when the cell harboring the fused protein is under hypoxic conditions than under aerobic conditions. The fused protein is degraded more quickly in the cell under aerobic conditions than under hypoxic conditions.
In the present invention, the term “hypoxic conditions” refers to a state where the partial pressure of oxygen is about 20 mmHg or less in vivo. For example, the culture of a cell in an incubator whose oxygen concentration is set to 1% or less is under hypoxic conditions. The term “aerobic conditions” refers to a state where the partial pressure of oxygen is higher than about 20 mmHg in vivo.
DNA of the first aspect of the present invention may be part of above-mentioned DNA as far as the polypeptide to be encoded by the DNA can provide stability dependent on an oxygen concentration in a cell as described above to a fused protein containing the polypeptide. Specifically, the polypeptide is a polypeptide having an amino acid sequence comprising at least 16 continuous amino acid residues in the amino acid sequence of SEQ ID NO: 1, preferably at least 17, more preferably at least 18. More specifically, the polypeptide is a polypeptide having an amino acid sequence comprising 16 or more amino acid residues in the amino acid sequence of SEQ ID NO: 1 and 120 or less amino acid, preferably 17 or more and 50 or less amino acid, more preferably 18 or more and 30 or less amino acid, particularly preferably 18 or more and 20 or less. Much more specifically, the polypeptide has the amino acid sequence consisting of amino acid Nos. 1 to 16 or of amino acid Nos. 3 to 18 in the amino acid sequence of SEQ ID NO: 1.
The polypeptide to be encoded by the DNA of the first aspect of the present invention may have an amino acid sequence including the substitution, deletion, or insertion of one or few amino acid residues in the amino acid sequence consisting of 15 or more and 20 or less continuous amino acid residues in the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having a homology of 85% or more with the polypeptide of the amino acid sequence of SEQ ID NO: 1 as far as the polypeptide can impart stability dependent on an oxygen concentration in a cell as described above to a fused protein containing the polypeptide. The tyrosine residue corresponding to the tyrosine residue of the amino acid No. 9 of the sequence of SEQ ID NO: 1 must be kept.
NLS has an amino acid sequence which is required for a protein to be localized in the nucleus of a eukaryotic cell having a nuclear membrane structure in the cell. That is, a protein having the above sequence is transported to the nucleus through a nuclear membrane. NLS has an amino acid sequence which is seen in a protein having activity in a nucleus, such as a DNA binding protein.
In the first aspect of the present invention, NLS is not particularly limited as long as a fused protein has the activity of transmigrating to the nucleus in a cell harboring the fused protein when the NLS is fused with a polypeptide to be encoded by the DNA of the first aspect of the present invention and other protein. The NLS is, for example, NLS (126a.a. to 132a.a. domain of large-T antigen) derived from the simian virus 40 (SV40) large-T antigen (Proc. Natl. Acad. Sci. (1989) 86:9327-9331: document 7). HIF-1α includes specific NLS, and this NLS may also be used.
The other protein is not particularly limited as long as the protein is used in the aim to control stability dependent on an oxygen concentration in a cell. The protein is, for example, a labeling protein or a protein having cytotoxicity.
Examples of the labeling protein include enzymes for catalyzing a color development reaction such as β-galactosidase, horseradish peroxidase and alkali phosphatase. The color development reactions of these are well known as enzyme immunoassay or a technique for investigating the existence of a protein in a cell in the fields of antibodies and microbiology. A protein having fluorescence such as green fluorescence protein (GFP) may be used as the above protein.
Examples of the protein having cytotoxicity include a toxic protein of thymidine kinase of a herpes simplex virus and an apoptosis inducible factor.
DNA of the first aspect of the present invention is not particularly limited as long as the amino acid sequence to be encoded satisfies the above conditions. Specifically, it is DNA having the nucleotide sequence of SEQ ID NO:2 or part thereof.
DNA of the first aspect of the present invention can be chemically synthesized according to a general chemical synthesis method based on the amino acid sequence to be encoded thereby. The amino acid sequence of HIF-1α or the nucleotide sequence of cDNA obtained by encoding the amino acid sequence thereof is already known (Gene Bank Accession No. U22431), and the DNA can also be obtained by amplification from the chromosome DNA or cDNA library of humans or animals such as mice by a polymerase chain reaction (PCR) using oligonucleotide prepared based on these sequences and nucleotide sequence of SEQ ID NO: 2 as a primer. Examples of the primer include various primers shown in Examples. When a sequence encoding NLS, a sequence required for the expression of a gene (such as a Kozak sequence), or a sequence which a restriction enzyme recognises is included in the sequence of the primer, the preparation of DNA encoding a fused protein becomes easy.
When the amplified product obtained by PCR is integrated into a host vector suitable for the recombination of a gene such as Escherichia coli, the subsequent operation becomes easy. An example of the vector is pBluescript II (TOYOBO).
The vector of the first aspect of the present invention is a vector which comprises DNA encoding NLS and DNA encoding a polypeptide of the first aspect of the present invention and which is capable of expressing a fused protein of a nuclear localization signal, the above polypeptide, and other protein by inserting DNA encoding other protein into these DNAs.
In the above vector, the DNA encoding a polypeptide is, specifically, DNA having the nucleotide sequence of SEQ ID NO: 2 or part thereof.
The DNA encoding NLS is, for example, DNA having the nucleotide sequence of SEQ ID NO: 6 or part thereof.
Another example of the vector of the first aspect of the present invention is a vector which comprises DNA encoding other protein, DNA encoding NLS, and DNA encoding a polypeptide according to the first aspect of the present invention, as described above to express a fused protein. The fused protein comprises NLS, the polypeptide according to the first aspect of the present invention, and other protein in this order from the N terminus. That is, in the vector of the first aspect of the present invention, DNAs encoding a polypeptide and a protein are connected to each other in such a manner that their frames are adjusted with each other, and further an expression control sequence such as a promoter required for the expression of a gene is contained.
The promoter includes, for example, an SV40 early promoter and lac promoter.
The cell of the first aspect of the present invention is a cell into which the vector of the first aspect of the present invention has been introduced. The cell may be the cell of a microorganism. Examples of the microorganism include: bacteria such as Escherichia coli; yeast such as Saccharomyces cerevisiae, filamentous fungi such as Aspergillus nidulans; and the cultured cells of animals or plants. To introduce the vector of the first aspect of the present invention into those cells, ordinary transformation may be used.
Escherichia coli DH5αIQ/PCH557-574 harboring the plasmid pCH/557-574 as an example of the vector containing the DNA of the first aspect of the present invention as will be shown in Example has been deposited at National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary (Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566 Japan) (formerly, National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (1-1-3 Higashi, Tsukuba, Ibaraki, 305-8566 Japan)) under the accession number FERM P-18193 on Feb. 1, 2001.
The above Escherichia coli DH5αIQ/PCH557-574 harboring the pCH/557-574 plasmid has been transferred to international depositary at the above International Patent Organism Depositary of National Institute of Advanced Industrial Science and Technology which is an independent administrative institution (Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566 Japan) as accession number FERM BP-7828 on Dec. 17, 2001.
A description is subsequently given of the method of utilizing a fused protein containing a polypeptide encoded by the DNA of the first aspect of the present invention.
The existence state of the fused protein of the first aspect of the present invention which is prepared by fusing together a nuclear localization signal, a polypeptide to be encoded by the DNA of the first aspect and other protein differs according to oxygen conditions in a cell.
Stated more specifically, the fused protein is existent stably in the cell under hypoxic conditions and is positively degraded in the cell under aerobic conditions.
Therefore, when the vector of the first aspect is introduced into a cell to express a fused protein to be encoded by the vector, the existence of a protein forming the fused protein of the first aspect can be controlled according to oxygen conditions in the cell.
Stated more specifically, a protein can be stably held by placing the cell under hypoxic conditions and the amount of a protein can be reduced by placing the cell under aerobic conditions.
When the vector of the first aspect which uses a labeling protein as other protein is held in the cell to express the fused protein of the first aspect containing the labeling protein and to monitor the labeling protein with the label as an index, in other words, to monitor the existence state of the fused protein of the first aspect, a cell under hypoxic conditions can be detected. Particularly when a protein which can be visualized as a label is used, a hypoxic cell can be visualized.
When the vector of the first aspect which uses a protein having cytotoxicity as other protein is held in a cell and the fused protein of the first aspect containing a protein having cytotoxicity is expressed in the cell, the growth of the cell under hypoxic conditions can be inhibited. More specifically, DNA encoding the fused protein of the first aspect is inserted into a retrovirus or adenovirus and the whole is administered into the body, a toxic protein can be expressed only in a hypoxic region in a tumor which is an issue in the scene of cancer treatment. Therefore, a cell under hypoxic conditions can be selectively removed, which may lead to the development of a new remedy for cancer.
A description is subsequently given of the fused protein of the second aspect of the present invention which is a fused protein containing the polypeptide according to the first aspect and having protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell.
The fused protein of the second aspect comprises NLS, a protein having protein transduction activity through membrane, other protein, and a polypeptide which imparts stability dependent on an oxygen concentration to the other protein in a cell harboring a fused protein obtained by fusing NLS and the other protein together. The fused protein can be transduced into the cell from the outside of the cell and has stability which differs according to oxygen conditions in the cell.
As the polypeptide in the fused protein of the second aspect, a polypeptide to be encoded by the above DNA of the first aspect, that is, the same polypeptide as the polypeptide in the fused protein of the first aspect may be used. More specifically, the polypeptide is a polypeptide having the amino acid sequence of SEQ ID NO: 1. As far as the polypeptide can impart stability dependent on an oxygen concentration in a cell, the polypeptide may have part of the amino acid sequence of SEQ ID NO: 1. The index for this part is described in the section of the above polypeptide to be encoded by the DNA of the first aspect.
The polypeptide in the fused protein of the second aspect is particularly preferably a polypeptide in the fused protein of the first aspect, that is, a polypeptide corresponding to the specific 557a.a.-574a.a. domain of HIF-1α having the sequence of SEQ ID NO: 1. The polypeptide in the fused protein of the second aspect has only to have the above specific domain. For example, a polypeptide corresponding to the 401a.a.-603a.a. domain of HIF-1α, preferably a polypeptide corresponding to the 548a.a.-603a.a. domain of HIF-1α may be used.
As NLS used in the fused protein of the second aspect, NLS the same NLS as NLS in the fused protein of the first aspect may be used.
The protein having protein transduction activity through membrane used in the fused protein of the second aspect is not particularly limited as long as the protein is a protein which imparts activity for transducing a protein through cell membrane to a fused protein obtained by being fused with the above polypeptide and other protein but the protein is preferably TAT, the third alpha-helix of Antennapedia homeodomain, VP22 protein from herpes simplex virus, or the like.
TAT is a protein having activity for transducing a protein through cell membrane derived from human immunodeficiency virus (HIV). More specifically, TAT is a protein having the amino acid sequence of SEQ ID NO: 4.
TAT as used in the present invention may have part of the amino acid sequence of SEQ ID NO: 4 as far as TAT has activity for transducing a protein through cell membrane. Specifically, TAT may be a protein having an amino acid sequence consisting of at least 9 amino acid residues in the amino acid sequence of SEQ ID NO: 4. More specifically, TAT may be a protein having the amino acid sequence consisting of amino acid Nos. 3 to 11 of the sequence of SEQ ID NO: 4.
As the other protein used in the fused protein of the second aspect, the same protein as the above-described other protein in the fused protein of the first aspect may be used. The other protein is, for example, a labeling protein or a protein having cytotoxicity like the above other protein.
Another example of the fused protein of the second aspect is a fused protein which comprises the above TAT, other protein, and a polypeptide which imparts stability dependent on an oxygen concentration to the other protein in a cell harboring the fused protein obtained by fusing TAT with the other protein. The fused protein can be transduced into the cell from the outside of the cell and has stability which differs according to oxygen conditions in the cell.
When the above TAT is used as the protein having protein transduction activity through membrane, a fused protein having protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell is obtained even though the protein does not have NLS. That is, when TAT is used as the protein having protein transduction activity through membrane, regardless of the existence of NLS, the fused protein of the second aspect is obtained.
The polypeptide and other protein in another example of the fused protein of the second aspect of the present invention have already been described in the section of the fused protein of the second aspect of the present invention.
The vector of the second aspect of the present invention is a vector capable of expressing the fused protein of the second aspect. Specifically, the vector is a vector which comprises DNA encoding NLS, DNA encoding a protein having protein transduction activity through membrane, and DNA encoding a polypeptide imparting stability dependent on oxygen concentration to the other protein in a cell harboring a fused protein obtained by fusing NLS with the other protein and which is capable of expressing a fused protein containing a nuclear localization signal, a protein having protein transduction activity through membrane, the above polypeptide, and other protein by inserting DNA encoding the other protein into these DNAs.
Another example of the vector of the second aspect of the present invention is a vector which comprises DNA encoding TAT and DNA encoding a polypeptide imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein obtained by fusing TAT with the other protein and which is capable of expressing a fused protein containing TAT, the above polypeptide, and other protein by inserting DNA encoding the other protein into these DNAs.
In the vector of the second aspect, the above DNA encoding a polypeptide is not particularly limited as long as the amino acid sequence of the polypeptide satisfies the conditions described in the section of the fused protein of the second aspect. Specifically, DNA encoding a polypeptide having 557a.a-574a.a. of HIF-1α is, for example, DNA having the nucleotide sequence of SEQ ID NO: 2 or part thereof. DNA encoding a polypeptide having 548a.a.-603a.a. of HIF-1α is, for example, DNA having the nucleotide sequence of SEQ ID NO: 3 or part thereof.
In the vector of the second aspect, DNA encoding NLS is, for example, DNA having the nucleotide sequence of SEQ ID NO: 6 or part thereof as described in the section of the vector of the first aspect.
In the vector of the second aspect, the DNA encoding a protein having protein transduction activity through membrane is, for example, DNA encoding TAT.
DNA encoding TAT is not particularly limited as far as DNA has activity for transducing a protein through cell membrane. Specifically, it is DNA encoding the amino acid sequence of SEQ ID NO: 4 or DNA for the encoding the amino acid sequence consisting of amino acids Nos. 3 to 11 in the amino acid sequence of SEQ ID NO: 4. More specifically, it is DNA having the nucleotide sequence of SEQ ID NO: 5 or part thereof.
Still another example of the vector of the second aspect of the present invention is a vector which comprises the above DNA encoding other protein and DNAs for encoding NLS, a protein having protein transduction activity through membrane and a polypeptide or comprises the above DNA encoding other protein and DNAs for encoding TAT and a polypeptide to express the fused protein of the second aspect. The fused protein of the second aspect comprises NLS, a protein having protein transduction activity through membrane, a polypeptide and other protein in this order from the N terminus. That is, in the vector of the second aspect, these DNAs for encoding a polypeptide and each type of proteins are connected to one another in such a manner that their frames are aligned with one another, and further an expression control sequence such as a promoter required for the expression of a gene is contained.
The promoter is, for example, an SV40 early promoter, lac promoter, or the like.
The cell into which the vector of the second aspect of the present invention is introduced is, for example, the cell of a microorganism. Examples of the microorganism include: bacteria such as Escherichia coli; yeast such as Saccharomyces cerevisiae; filamentous fungi such as Aspergillus nidulans; and the cultured cells of animals or plants.
Escherichia coli LMPG194/pBAD3-0 and LMPG194/pBAD557-574 described above respectively harboring the plasmids pBAD/3-0 and pBAD/557-574 has been transferred to international depositary at the above International Patent Organism Depositary of National Institute of Advanced Industrial Science and Technology which is an independent administrative institution Central 6, Higashi, Tsukuba, Ibaraki, 305-8566 Japan) as accession Nos. FERM BP-7809 and FERM BP-7810 on Nov. 26, 2001, respectively.
Escherichia coli LMPG194/pBAD3-0 and LMPG194/pBAD557-574 described above respectively harboring the plasmids pBAD/3-0 and pBAD/557-574 has been transferred to international depositary at the above International Patent Organism Depositary of National Institute of Advanced Industrial Science and Technology which is an independent administrative institution (Central 6, Higashi, Tsukuba, Ibaraki, 305-8566 Japan) as accession Nos. FERM BP-7809 and FERM BP-7810 on Nov. 26, 2001, respectively.
A description is subsequently given of the method of controlling the existence of a fused protein using the fused protein of the second aspect.
The controlling method comprises allowing the above fused protein of the second aspect to be transduced into the cell from the outside of the cell; and controlling the existence state of the fused protein of the second aspect according to oxygen conditions in the cell. When the fused protein of the second aspect is used, the protein can be introduced into the cell advantageously. The expression “introduced” means that the fused protein is transduced into the cell from the outside of the cell and also includes a case where the fused protein is discharged from the inside of a certain cell to the outside of the cell and is introduced into another cell.
The expression “controlling the existence state of the fused protein according to oxygen conditions” means that the fused protein of the second aspect is controlled to be existent more stably in the cell under hypoxic conditions than under aerobic conditions as described in the section of the fused protein of the first aspect.
When the existence state of the fused protein is monitored by using the method of controlling the existence state of the fused protein of the second aspect and a labeling protein as the other protein with the label as an index, a cell under hypoxic conditions can be detected as having already been described in the section of the method of controlling the existence state of the fused protein of the first aspect.
When the fused protein of the second aspect is made existent in a cell under hypoxic conditions by using the method of controlling the existence state of the fused protein and using a protein having cytotoxicity as the other protein, the growth of the cell under hypoxic conditions can be inhibited as having already been described in the section of the method of controlling the existence state of the fused protein of the first aspect.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic diagram of pCH/0-0 plasmid.
FIG. 2 is a schematic diagram of pCH/0-0 to pCH/4-0 plasmids.
FIG. 3 is a schematic diagram of pCH series of plasmids.
FIG. 4 is a schematic diagram of pCH/3-0 (ΔNLS) and pCH/557-574 (ΔNLS) plasmids.
FIG. 5 shows photos showing the results of X-gal staining.
FIG. 6 is a schematic diagram of the structure of each fused protein.
FIG. 7 shows photos showing the results of X-gal staining.
FIG. 8 shows photos showing the results of X-gal staining.
FIG. 9 shows photos showing observation of apoptosis dependent on an oxygen concentration in Example 6.



BEST MODE FOR CARRYING OUT THE INVENTION
The following examples are given to illustrate the present invention in further detail.
[A: Material and Method]
<1> Construction of NLS/HIF-1α ODD Domain/lacZ Fused Gene Expression Plasmid
All the identified vectors were produced based on the pCH110 Eukaryotic Assay Vector plasmid (Amersham Pharmacia Biotech). The plasmid has a Simian virus 40 early promoter.
(1) Plasmids: Construction of pCH/0-0, 0-1, 0-2, 0-3, 1-2, 1-3, 1-0, 2-0, 3-0, 3-4, and 4-0 (FIGS. 1 and 2)
DNA of Kozak sequence (nucleotide Nos. 8-14 of sequence of SEQ ID NO: 7) (Nucl. Acid Res. (1987) vol. 15, 20, 8125-8131: document 8) and DNA contained DNA encoding NLS (nuclear localization signal) (document 7) (nucleotide Nos. 17-37 of sequence of SEQ ID NO: 7) were first synthesized, annealed in each and treated with the HindIII and BgIII restriction enzymes. Thereafter, the ODD domain (Oxygen Dependent Degradation domain) of human HIF-1α was amplified from human cDNA by PCR and treated with the BglII and KpnI restriction enzymes. The above DNA fragments were inserted between the HindIII site and KpnI site of pCH110/NLS by three-molecule ligation so that their translation frames were aligned with each other. The synthesized DNAs used for PCR are listed below.
1) Kozak ATG/NLS sense DNA (SEQ ID NO: 7) taagcttgacatggcgcctaagaagaagaggaagagatctg
2) Kozak ATG/NLS antisense DNA (SEQ ID NO: 8) cagatctcttcctcttcttcttaggcgccatgtcaagctta
3) ODD-BglII.FO primer (SEQ ID NO: 9) gagatctgccccagccgctggagacacaa
4) ODD-BglII.F1 primer (SEQ ID NO: 10) ggagatctttggcaatgtctccattacccacc
5) ODD-BglII.F2 primer (SEQ ID NO: 11) ggagatctcctagtccttccgatggaagcact
6) ODD-BglII.F3 primer (SEQ ID NO: 12) ggagatctaacccattttctactcaggacaca
7) ODD-BglII.F4 primer (SEQ ID NO: 13) ggagatctcagttgtcaccattagaaagcagt
8) ODD-KpnI.RO antisense primer (SEQ ID NO: 14) aggtacctgctggaatactgtaactgtgc
9) ODD-KpnI.R1 antisense primer (SEQ ID NO: 15) aaggtacctgatttatattctgtaatttttcgtt
10) ODD-KpnI.R2 antisense primer (SEQ ID NO: 16) aaggtacctgtgtctgatcctgaatctggggcat
11) ODD-KpnI.R3 antisense primer (SEQ ID NO: 17) aaggtacctgctttgcttctgtgtcttcagcaaa
12) ODD-KpnI.R4 antisense primer (SEQ ID NO: 18) aaggtacctgtaatggtgacaactgatcgaagga
Combinations of primers used for amplification of the ODD domain inserted into the respective plasmids by PCR are listed below.











TABLE 1







Plasmid
Sense primer
Anti-sense primer









pCH/0-0
ODD-Bgl II.F0
ODD-Kpn I.R0



pCH/0-1
ODD-Bgl II.F0
ODD-Kpn I.R1



pCH/0-2
ODD-Bgl II.F0
ODD-Kpn I.R2



pCH/0-3
ODD-Bgl II.F0
ODD-Kpn I.R3



pCH/1-2
ODD-Bgl II.F1
ODD-Kpn I.R2



pCH/1-3
ODD-Bgl II.F1
ODD-Kpn I.R3



pCH/1-0
ODD-Bgl II.F1
ODD-Kpn I.R0



pCH/2-0
ODD-Bgl II.F2
ODD-Kpn I.R0



pCH/3-0
ODD-Bgl II.F3
ODD-Kpn I.R0



pCH/3-4
ODD-Bgl II.F3
ODD-Kpn I.R4



pCH/4-0
ODD-Bgl II.F4
ODD-Kpn I.R0










Each plasmid was subjected to gene recombination so that the ODD domain shown in Table 2 was fused with NLS and lacZ gene at a protein level. “a.a.” shows the position of the amino acid residue in the ODD domain. In Table 2, for example, pCH/0-0 means that a DNA strand encoding positions from 401 to 603 in the ODD domain was fused with a DNA strand for encoding NLS and lacZ gene.










TABLE 2







Plasmid
Fused protein









pCH/0-0
NLS/HIF-1α 401a.a.-603a.a./β-Gal



pCH/0-1
NLS/HIF-1α 401a.a.-447a.a./β-Gal



pCH/0-2
NLS/HIF-1α 401a.a.-500a.a./β-Gal



pCH/0-3
NLS/HIF-1α 401a.a.-547a.a./β-Gal



pCH/1-2
NLS/HIF-1α 448a.a.-501a.a./β-Gal



pCH/1-3
NLS/HIF-1α 448a.a.-547a.a./β-Gal



pCH/1-0
NLS/HIF-1α 448a.a.-603a.a./β-Gal



pCH/2-0
NLS/HIF-1α 501a.a.-603a.a./β-Gal



pCH/3-0
NLS/HIF-1α 548a.a.-603a.a./β-Gal



pCH/3-4
NLS/HIF-1α 548a.a.-583a.a./β-Gal



pCH/4-0
NLS/HIF-1α 579a.a.-603a.a./β-Gal










In FIG. 1, FO and RO represent the positions of primers used for PCR. The bold line in FIG. 1 shows an ODD domain fused with the lacZ gene in each plasmid and the length of the domain. pCH/0-0 shows that a DNA strand encoding positions from 401 to 603 of the ODD domain and DNA strands encoding NLS and the lacZ gene were fused together. In FIG. 2, F0, F1, F2, F3, F4, R0, R1, R2, R3, and R4 indicate the positions of primers used for PCR, respectively.
(2) Construction of pCH/557-574, 562-569, 557-571, 560-574, 557-574 (Y565A), and 557-574 (ΔNLS) Plasmids (FIG. 3)
DNAs for encoding part of the ODD domain (Oxygen Dependent Degradation domain) of human HIF-1α (sequence Nos. 19-28) were first synthesized, annealed in each combination, and inserted between the BglII site and KpnI site of pCH110/3-0 so that their translation frames were aligned with one another. The synthesized DNAs used are listed below.
13) ODD 557-574 sense DNA (SEQ ID NO: 19) gatctttagacttggagatgttagctccctatatcccaatggatgatgacttccag ttacaggtac
14) ODD 557-574 antisense DNA (SEQ ID NO: 20) ctgtaactggaagtcatcatccattgggatatagggagctaacatctccaagtcta aa
15) ODD 562-569 sense DNA (SEQ ID NO: 21) gatctttagctccctatatcccaatggatcaggtac
16) ODD 562-569 antisense DNA (SEQ ID NO: 22) ctgatccattgggatatagggagctaaa
17) ODD 557-571 sense DNA (SEQ ID NO: 23) gatctttagacttggagatgttagctccctatatcccaatggatgatgaccaggta c
18) ODD 557-571 antisense DNA (SEQ ID NO: 24) ctggtcatcatccattgggatatagggagctaacatctccaagtctaaa
19) ODD 560-574 sense DNA (SEQ ID NO: 25) gatctgagatgttagctccctatatcccaatggatgatgacttccagttacaggta c
20) ODD 560-574 antisense DNA (SEQ ID NO: 26) ctgtaactggaagtcatcatccattgggatatagggagctaacatctca
21) ODD 557-574 Y565A sense DNA (SEQ ID NO: 27) gatctttagacttggagatgttagctcccgctatcccaatggatgatgacttccag ttacaggtac
22) ODD 557-574 Y565A antisense DNA (SEQ ID NO: 28) ctgtaactggaagtcatcatccattgggatagcgggagctaacatctccaagtcta aa
Each plasmid was subjected to gene recombination so that the ODD domain shown in Table 3 was fused with NLS, and lacZ gene at a protein level.








TABLE 3





Plasmid
Fused protein







pCH/557-574
NLS/HIF-1α 557a.a.-574a.a./β-Gal


pCH/562-569
NLS/HIF-1α 562a.a.-569a.a./β-Gal


pCH/557-571
NLS/HIF-1α 557a.a.-571a.a./β-Gal


pCH/560-574
NLS/HIF-1α 560a.a.-574a.a./β-Gal


pCH/557-574(Y565A)
NLS/HIF-1α 557a.a.-574a.a. (Y565A)/β-Gal









In FIG. 3, “L”, “D”, and the like represent respective amino acid sequences in the ODD domain fused with the lacZ gene in each plasmid. For example, pCH/562-569 means that a DNA strand encoding “LAPYIPMD (SEQ ID NO: 29)” and a DNA strand encoding NLS and the lacZ gene were fused together.
(3) <1-3> Construction of pCH/557-574 (ΔNLS) and 3-0 (ΔNLS) Plasmids (FIG. 4)
pCH/557-574 (ΔNLS) and pCH/3-0 (ΔNLS) were produced based on pCH/557-574 and pCH/3-0, respectively. The HindIII-BglII region including the Kozak sequence and NLS (nuclear localization signal) was cut out from pCH/557-574 and pCH/3-0, the following DNAs for encoding only the Kozak ATG sequence were synthesized instead, and DNA fragments obtained by annealing the DNAs were inserted.
23) Kozak ATG sense DNA (SEQ ID NO: 30) agcttgacatggcga
24) Kozak ATG antisense DNA (SEQ ID NO: 31) gatctcgccatgtca
Each plasmid was subjected to gene recombination so that the ODD domain shown in Table 4 was fused with lacZ gene at a protein level.










TABLE 4







Plasmid
Fused protein









pCH/557-574 (ΔNLS)
HIF-1α 557a.a.-574a.a./β-Gal



pCH/3-0 (ΔNLS)
HIF-1α 548a.a.-603a.a./β-Gal










In FIG. 4, the bold line indicates the length of the ODD domain fused with the lacZ gene in each plasmid. For example, pCH/3-0 (ΔNLS) means that a DNA strand encoding the 548a.a.-603a.a. ODD domain and a DNA strand encoding the lacZ gene were fused together.
<2> Cell Culture
The HEK293 (derived from human embryo kidney) cells were cultured in a 5% CO2 incubator at 37° C. using a Dubecco's MEM medium (GIBCO BRL) containing 5% of FCS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin (of Meiji Pharmaceuticals) as an ordinary medium.
<3> DNA Transfection and X-Gal Staining
1×105 HEK293 cells (Graham F L, Smiley J, Russel W C, and Nairn R., J Gen Virol. 36(1): 59-74, 1977: document 10) were planted onto a 6-well plate, and 5 μg of a plasmid was introduced into the cells by a calcium phosphate transformation method (Chen, C. and H. Okayama., Mol. Cell. Biol. 7: 2745-2752, 1987: document 11) on the following day. After 24 hours of culture in a 3% CO2 incubator at 37° C., the cells were removed from the dish by trypsin treatment, divided into two aliquots and plated onto a 6-well plate. To make a hypoxia-mimic condition for inhibiting a ubiquitin-proteasome system, in other words, for HIF-1α protein stability, 50 μM of Cbz-LLL (document 3) was added to one of the two aliquots and cultured for 24 hours. Thereafter, X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) staining (Sanes, J. R., J. L. Rubenstein and J. F. Nicolas. 1986. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J.5: 3133-3142: document 12) was carried out.
Example 1
1> Confirmation of Control of Cbz-LLL-Dependent Stability of Fused Protein of ODD Domain
To study whether the stability of a protein fused with the ODD domain (401a.a.-603a.a. region) of the HIF-1α protein can be controlled depending on oxygen concentration, the pCH/0-0 plasmid (NLS/HIF-1α 401a.a.-603a.a./lacZ) was produced by fusing the ODD domain (401a.a.-603a.a.) with NLS and the lacZ gene ([A: Material and method] <1> (1)). Note that the NLS sequence was encoded for the wild type HIF-1α, so that pCH/0-0 was produced by fusing NLS with the ODD domain.
1×105 HEK293 cells were planted onto a 6-well plate, and 5 μg of the pCH/0-0 plasmid was introduced into the cells by a calcium phosphate transformation method on the following day. After 24 hours of culture in a 3% CO2 incubator at 37° C., the cells were divided into two aliquots by EDTA treatment. One was cultured in an ordinary medium, and the other was cultured in a medium containing 50 μM of Cbz-LLL, for 24 hours. Finally, X-gal staining was carried out to confirm the expression of a fused protein. The results are shown in Table 5.
As the result of X-gal staining, the number of cells stained blue and the density of the stained color were significantly reduced in the case of culture in the absence of Cbz-LLL as compared with culture in the presence of Cbz-LLL. In Table 5 (the same shall apply hereinafter), when there is a difference in the stability of the fused protein between the presence and absence of Cbz-LLL, that is, when it can be observed that the stability of the fused protein can be controlled depending on Cbz-LLL, a symbol + (plus) is given.
Meanwhile, when the pCH110 plasmid containing no ODD domain was introduced, there was seen no difference in the number of cells stained blue and the density of the stained color between the presence and absence of Cbz-LLL. In Table 5 (the same shall apply hereinafter), when no difference in the stability of a fused protein between the presence and absence of Cbz-LLL is observed, a symbol − (minus) is given.










TABLE 5








Control of Cbz-LLL dependent stability



Plasmid
of fused protein









pCH110
−



pCH/0-0
+










Since it is reported that Cbz-LLL does not affect transfer activity and the stability of mRNA, these results show that the stability of β-galactosidase (β-gal) protein can be controlled depending on Cbz-LLL by fusing the 401a.a.-603a.a. region of HIF-1α.
<2> Identification of Region Required for Control of Cbz-LLL Dependent Stability of Fused Protein of ODD Domain
(1) To identify a region in the ODD domain indispensable for the control of Cbz-LLL dependent stability of a fused protein, the N terminus and/or C terminus of the ODD domain are/is systematically deleted, and a plasmid was produced by fusing NLS and the lacZ gene (refer to [A: Material and method] <1> (1)) and introduced into the HEK293 cells as in the above <1>, and the HEK293 cells were stained with X-gal. The results are shown in Table 6.
As a result, when pCH/0-1, 0-2, 0-3, 1-2, 1-3, and 4-0 were introduced, there was seen no difference in the number of cells stained blue and the density of the stained color between the presence and absence of Cbz-LLL. Meanwhile, when pCH/1-0, 2-0, 3-0, and 3-4 were introduced into cells to culture them in the absence of Cbz-LLL, the number of cells stained blue and the density of the stained color were significantly reduced as compared with when they were cultured in the presence of Cbz-LLL.










TABLE 6








Control of Cbz-LLL dependent



Plasmid
stability of fused protein









pCH/0-1
−



pCH/0-2
−



pCH/0-3
−



pCH/1-2
−



pCH/1-3
−



pCH/1-0
+



pCH/2-0
+



pCH/3-0
+



pCH/3-4
+



pCH/4-0
−










It was found from these results that the 548a.a.-583a.a. region of HIF-1α is important for the control of Cbz-LLL dependent stability of a fused protein. Note that the results of pCH/3-0 stained with X-gal are compared with those of pCH110 and shown in FIG. 5. In FIG. 5, A and B show HEK293 cells into which the pCH110 plasmid was introduced. On the other hand, C and D show HEK293 cells into which pCH/3-0 was introduced. Also, B and D show cells which were cultured in a medium containing Cbz-LLL, and A and C show cells which were cultured in a medium containing no Cbz-LLL.
(2) When known databases were searched for the homology of the 548a.a.-583a.a. region of the ODD domain of human HIF-1α, it was found that the region comprises a sequence (557a.a.-574a.a.) consisting of 18 amino acid residues kept in not only human HIF-1α but also the HIF-1α of a mouse. The pCH/557-574 plasmid was produced by fusing the 557a.a.-574a.a. region of HIF-1α with the lacZ gene (refer to [A: Material and method] <1> (2) and FIG. 3) and introduced into the HEK293 cells as in the above <2>, and the obtained cells were stained with X-gal.










TABLE 7








Control of Cbz-LLL dependent



Plasmid
stability of fused protein









pCH/3-4
+



pCH/557-574
+










As a result, when pCH/557-574 was introduced into the cells and the cells were cultured in the absence of Cbz-LLL, the number of cells stained blue and the density of the stained color were significantly reduced as compared with when they were cultured in the presence of Cbz-LLL. This shows that the stability of β-gal protein is dependent on Cbz-LLL by fusing only the 557a.a.-574a.a. region.
(3) Subsequently, the pCH/562-569, 557-571, and 560-574 plasmids (562a.a.-569a.a., 557a.a.-571a.a., and 560a.a.-574a.a. of HIF-1α were respectively fused with NLS and LacZ) having a shorter HIF-1α region to be fused with β-gal protein were produced (refer to [A: Material and method] <1> (2) and FIG. 3) and introduced into the HEK293 cells as in the above <2>, and the obtained cells were stained with X-gal. The results are shown in Table 8.










TABLE 8








Control of Cbz-LLL dependent



Plasmid
stability of fused protein









pCH/3-4
+



pCH/557-574
+



pCH/562-569
−



pCH/557-571
−



pCH/560-574
−










As a result, when these plasmids were introduced, there was seen no difference in the number of cells stained blue and the density of the stained color between the presence and absence of Cbz-LLL.
It was found from the above results that the 557a.a.-574a.a. region of HIF-1α must be fused to make the stability of β-gal protein significantly dependent on Cbz-LLL.
<3> Importance of 557a.a.-574a.a. Region of ODD Domain for Control of Cbz-LLL Dependent Stability of Tyrosine Residue
It is known that the degradation of a protein by a ubiquitin/proteasome system is controlled by a change in the phosphorylation state of a target protein. Then it is conceived that the degradation of the produced fused protein by a ubiquitin system may be controlled by a change in the phosphorylation state. The pCH/557-574 (Y565A) plasmid was produced by substituting the tyrosine residue at the 565-position which is the only amino acid able to be phosphorylated in the HIF-1α 557a.a-574a.a. of the pCH/557-574 plasmid with the alanine residue (refer to [A: Material and method] <1> (2) and FIG. 3) and introduced into the HEK293 cells as described above, and the obtained cells were stained with X-gal. The results are shown in Table 9.










TABLE 9








Control of Cbz-LLL dependent



Plasmid
stability of fused protein









pCH/557-574
+



pCH/557-574 (Y565A)
−










As a result, when pCH/557-574 (Y565A) was introduced, there was seen no difference in the number of cells stained blue and the density of the stained color between the presence and absence of Cbz-LLL. It was thereby made clear that the tyrosine residue at the 565-position is an especially important amino acid for the stability of a protein fused with the 557a.a.-574a.a. of HIF-1α.
Example 2
To check whether NLS (nuclear localization signal) is required for the control of the Cbz-LLL dependent stabilities of a series of fused proteins, the pCH/557-574 (ΔNLS) and pCH/3-0 (ΔNLS) plasmids were produced by deleting NLS from pCH/557-574 and pCH/3-0, respectively (refer to [A: Material and method] <1> (3) and FIG. 4) and introduced into the HEK293 cells as in Example 1, and the obtained cells were stained with X-gal. The results are shown in Table 10.










TABLE 10








Control of Cbz-LLL dependent



Plasmid
stability Of fused protein









pCH3-0 (ΔNLS)
−



pCH/557-574(ΔNLS)
−










As a result, there was seen no difference in the number of cells stained blue and the density of the stained color between the presence and absence of Cbz-LLL. It was thereby confirmed that NLS takes part in the control of Cbz-LLL dependent stability of a fused protein.
[B: Material and Method]
A general operation used in Example 3 et seq. will be described hereinbelow.
The annealing of the synthesized oligonucleotides was carried out as follows. 10 μl of a synthesized single-stranded oligonucleotide (concentration of 100 μl) was mixed with 10 μl of another synthesized oligonucleotide which is complementary to the above oligonucleotide, and 20 μl of a NaCl solution (1 M) and 160 μl of purified water were added to the mixture to prepare 200 μl of a reaction solution in total. This solution was heated at 95° C. for 1 minute, kept at 75° C. for 1 minute, and gradually cooled to 37° C. at a rate of 1° C./2 minutes. Then, 10 μl of a sodium acetate solution (3 M) and 250 μl of ethanol were added to 100 μl of the DNA solution, and the resultant mixture was centrifuged at 12 krpm for 10 minutes (4° C.). Thereafter, the supernatant was discarded, the precipitate was washed with 70% ethanol, and the 70% ethanol was removed in the end to obtain purified DNA.
As for a treatment with a restriction enzyme, 1 μg of plasmid DNA purified by ethanol precipitation was dissolved in 10 μl of a universal buffer (TAKARA Biomedical) and 90 μl of purified water, and a target restriction enzyme was added to the solution and maintained at 37° C. for 30 minutes after pipetting.
The separation (excision) of a DNA fragment was carried out as follows. To isolate the target DNA fragment which was treated with the restriction enzyme from other DNA fragments, agarose gel (containing EtBr) electrophoresis was first carried out. This agarose gel was exposed to light from a UV lamp having a wavelength of 365 nm to visualize the DNA fragment and the agarose gel containing the target DNA fragment was cut out with a razor. Finally, the target DNA fragment was extracted from this agarose gel using the QIAquick gel extraction kit (Qiagen) and purified.
Ligation was carried out in vitro using the DNA ligation kit Ver. 2 (TAKARA Biomedical) following the procedure of this kit for the phosphodiester binding of a plurality of DNA fragments. The amounts of the vector DNA fragment and the DNA fragment to be inserted used in ligation were both 10 ng.
Example 3
Construction of Plasmid for Expressing ODD Domain, 6 His Residues, NLS, TAT and lacZ Fused Gene
<1> Construction of Plasmid Containing NLS, HIF-1 ODD Domain and lacZ Fused Gene
The construction of the pCH/3-0 plasmid and the pCH/557-574 plasmid was carried out in accordance with the method described in [A: Material and method] <1> (1) and (2) (See also Tables 2 and 3 and FIGS. 1 to 3).
<2> Construction of Plasmid for Expressing His/NLS/TAT/HIF-1α ODD Domain/lacZ Fused Gene
The above identified vectors were produced based on the pBAD plasmid/His/lacZ Vector (Invitrogen).
(1) Construction of pCH/TAT/3-0 and pCH/TAT/557-574 Plasmids
DNA fragments obtained by annealing the following synthetic oligo-DNAs (sequence Nos. 32 and 33) for encoding a TAT sequence were integrated into a vector obtained by treating pCH/3-0 or pCH/557-574 with the BglII restriction enzyme to obtain pCH/TAT/3-0 and pCH/TAT/557-574.
25) TAT.BglII sense DNA (SEQ ID NO: 32) gat cat atg gtc gta aga aac gtc gcc aac gtc gcc gaa
26) TAT.BglII antisense DNA (SEQ ID NO: 33) qat ctt cgg cga cgt tgg cga cgt ttc tta cga cca tat
(2) Construction of pBAD/3-0 and pBAD/557-574 Plasmids
The pBAD plasmid/His/lacZ Vector has two BamHI sites. After only the digestion site of the 413th nucleotide was cut off, the DNA end was made blunt. Subsequently, about 5,170 bp of a DNA fragment produced by digesting the vector with the SacI restriction enzyme was cut out by agarose gel electrophoresis and designated as pBAD/His/lacZ BamHI-SacI vector. Meanwhile, after pCH/TAT/3-0 and pCH/TAT/557-574 were digested with the HindIII restriction enzyme, their DNA ends were made blunt. About 2,250 bps of a DNA fragment produced by treating with the SacI restriction enzyme was cut out by agarose gel electrophoresis. These DNA fragments were ligated with the pBAD/His/lacZ BamHI-SacI vector to obtain pBAD/3-0 and pBAD/557-574.
(3) Construction of pBAD/P.C. Plasmid
The pCH/3-0 was first treated with the HindIII and KpnI restriction enzymes to produce about 6,900 bps of a DNA fragment which was then cut out by agarose gel electrophoresis. The following synthetic DNA fragments (sequence Nos. 34 and 35) for encoding Kozak ATG and NLS were annealed and inserted into the above DNA fragment to obtain pCH/P.C.
27) Kozak ATG/NLS HindIII sense DNA (SEQ ID NO: 34) agc ttg aca tgg cgc cta aga aga aga gga agc agg tac
28) Kozak ATG/NLS KpnI antisense DNA (SEQ ID NO: 35) ctg ctt cct ctt ctt ctt agg cgc cat gtc a
Thereafter, the following synthetic oligo-DNA fragments (sequence Nos. 36 and 37) for encoding a TAT sequence were annealed and integrated into a vector obtained by treating pCH/P.C. with the KpnI restriction enzyme to produce pCH/TAT/P.C.
29) TAT.KpnI sense DNA (SEQ ID NO: 36) gat atg gtc gta aga aac gtc gcc aac gtc gcc gac agg tac
30) TAT KpnI antisense DNA (SEQ ID NO: 37) ctg tcg gcg acg ttg gcg acg ttt ctt acg acc ata tcg tac
Subsequently, after pCH/TAT/P.C. was digested with the HindIII restriction enzyme, its DNA end was made blunt. About 2,000 bps of a DNA fragment produced by treating with the SacI restriction enzyme was cut out by agarose gel electrophoresis. This was ligated with the pBAD/His/lacZ BamHI-SacI vector to obtain pBAD/P.C.
(4) Explanation of Each Plasmid
In pBAD/P.C., pBAD/3-0 and pBAD/557-574, the ODD domain shown in Table 11 below, six His residues, TAT, NLS, and lacZ genes are fused at a protein level (see FIG. 6).
Note that in Table 11, “a.a.” shows the position of the amino acid residue in the ODD domain. In Table 11, for example, pAD/3-D shows that a DNA strand encoding positions from 548 to 603 of the ODD domain and DNA strands for encoding His, NLS, TAT, and lacZ gene were fused together.
Also, FIG. 6 is a schematic diagram of the structure of each fused protein. In the present invention, a plasmid for expressing each fused protein was produced to have an active region as shown in FIG. 6.
In FIG. 6, “6×His” denotes a region having six continuous histidine residues, “NLS” a nuclear localization signal derived from SV 40 large T antigen, “TAT” a TAT signal sequence derived from HIV (Cell; 55, 1179 (1988), Proc. Natl. Acad. Sci. USA; 91, 664 (1994)), “ODD” an Oxygen Dependent Degradation domain derived from a human HIF-1α gene, and “β-gal” an E. coli lacZ gene product. N.C.β-gal was a wild β-gal protein. The oxygen dependent degradation domains derived from a human HIF-1α gene and fused with 3-0 β-gal and 557-574 β-gal are HIF-1α548a.a.-603a.a. and HIF-1α557a.a.-574a.a., respectively.










TABLE 11







Plasmid
Fused protein









pBAD/P.C.
6xHis/NLS/TAT/β-Gal



pBAD/3-0
6xHis/NLS/TAT/HIF-1α548a.a.-603a.a./β-Gal



pBAD/557-574
6xHis/NLS/TAT/HIF-1α557a.a.-574a.a./β-Gal










All the nucleotide sequences of the respective plasmids are shown in Table 12.










TABLE 12







Plasmid
SEQ ID NO:









pCH/TAT/3-0
38



pCH/TAT/557-574
40



pBAD/3-0
42



pBAD/557-574
44



pCH/P.C.
46



pCH/TAT/P.C.
48



pBAD/P.C.
50










Also, amino acid sequences to be encoded by genes in the respective plasmids are shown in Table 13.










TABLE 13







Plasmid
SEQ ID NOS:









pCH/TAT/3-0
39



pCH/TAT/557-574
41



pBAD/3-0
43



pBAD/557-574
45



pCH/P.C.
47



pCH/TAT/P.C.
49



pBAD/P.C.
51










Example 4
Confirmation of Cbz-LLL Dependent Stability of Fused Protein
<1> Purification of Fused Protein
The E. coli LMG194 strain was transformed by using three expression vectors, a) pBAD/P.C., b) pBAD/3-0 and c) pBAD/557-574. On the following day, a single colony was picked up from each of these culture plates, planted to 10 ml of a TB medium (containing 50 μg/ml of ampicillin), and cultured with shaking at 37° C. On the next day, 1 ml of each overnight culture was added to 200 ml of a TB medium (containing 50 μg/ml of ampicillin) and cultured with shaking at 37° C. When the absorbance OD600 of each culture liquid reached 0.5, 0.4 g of L-(+)-arabinose was added to each culture liquid to induce the expression of a fused protein, and culture was continued until the following day.
The rough purification of the fused protein was next carried out in accordance with an attached protocol using Ni-NTA agarose (QIAGEN). To further improve the purification of the roughly purified fused protein, also enhance the concentration of the fused protein, and further substitute a buffer solution to PBS, MICROCON YM-100 (AMICON) was used in accordance with the attached protocol.
<2>
In the following operation, the A549 cell (derived from human lung cancer) was cultured in a 5% CO2 incubator at 37° C. using a Dulbecco's MEM medium (GIBCO BRL) containing 5% of FCS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin (Meiji Pharmaceuticals) as an ordinary medium.
1×104 A549 cells were scattered over a 24-hole multiwell dish, and each well was cleaned with serum-free D-MEM twice on the following day. A fused protein shown in Table 14 below was added to this and cultured in a 5% CO2 incubator at 37° C. for 30 minutes.












TABLE 14









Amount of
Amount of



Well No.
Fused protein
protein
medium









1, 2
N.C. protein (※1)
0.2 U
0.2 ml



3, 4
P.C. protein
0.2 U
0.2 ml



5, 6
3-0 protein
0.2 U
0.2 ml



7, 8
557-574 protein
0.2 U
0.2 ml










Note that in Table 14, ※1 means that a wild β-gal protein was used as N.C. protein. Also, “U” represents the amount of a protein required for 1 μM of ONPG (o-nitrophenyl-b-D-lactopyranoside) to be degraded to o-nitrophenol and galactose at 37° C. and a pH of 7.5 in 1 minute.
Then, after the respective wells were cleaned with serum-free D-MEM twice again, well Nos. 1, 3, 5, and 7 were cultured in an ordinary medium and well Nos. 2; 4, 6, and 8 were cultured in a medium containing 50 μM of Cbz-LLL (document 3) for 20 hours as in a cell under hypoxic conditions to inhibit a ubiquitin-proteasome system. Thereafter, X-gal staining (document 12) was carried out.
As a result, a blue stained cell was not observed among the A549 cells to which the N.C. protein was added regardless of the existence of Cbz-LLL. On the other hand, all the A549 cells to which the P.C. protein was added were stained blue regardless of the existence of Cbz-LLL (see FIGS. 7A and B). This shows that the fused protein was introduced into the cell by the activity of the TAT region derived from HIV and fused with the added protein.
When Cbz-LLL was added to the A549 cells to which the 3-0 protein was added, a cell stained significantly strong was seen among them (see FIGS. 7C and D). This indicates that the stability of the fused protein is increased in the presence of Cbz-LLL by the activity of the ODD domain (548a.a.-603a.a. of HIF-1α) fused with the 3-0 protein. Even when the same experiments were conducted by adding the 557-574 protein, the same results as those obtained with the 3-0 protein could be obtained.
Note that in FIG. 7, A and B show cells into which P.C. β-gal was introduced, and C and D show cells to which 3-0 β-gal was added. Also, A and C show cells which were cultured in a medium containing no Cbz-LLL, and B and D show cells which were cultured in a medium containing Cbz-LLL.
Example 5
Confirmation of Oxygen Concentration Dependent Stability of Fused Protein
X-gal staining was carried out in the same manner as in Example 4 except that the method of forming hypoxic conditions was changed as follows.
The fused protein was added and then removed after 30 minutes. Thereafter, 20% O2 gas was supplied to the medium to obtain aerobic conditions, 1% O2 gas was supplied to the medium to obtain hypoxic conditions, and culture was carried out for about 24 hours. Finally, X-gal staining was performed.
As a result, all the A549 cells to which the P.C. protein was added were stained blue regardless of the concentration of oxygen (see FIGS. 8A and B).
On the other hand, when 1% O2 gas was supplied to obtain hypoxic conditions, a cell stained significantly strong was seen among the A549 cells to which the 3-0 protein was added (see FIGS. 8C and D).
Note that in FIG. 8, A and B show cells to which P.C. β-gal was introduced, and C and D show cells to which 3-0 β-gal was added. Also, A and C show cells cultured in a medium to which 20% O2 gas was supplied (aerobic condition), and B and D show cells cultured in a medium to which 1% O2 gas was supplied (hypoxic condition).
Example 6
Confirmation of Oxygen Concentration Dependent Stability of Fused Protein
<1> Construction of TAT-ODD-Caspase 3 Fused Protein Expression Vector (pGEX/TAT-ODD3-0-Casp3)
PCR was first carried out using the following two synthetic oligo-DNAs and pBAD/3-0 as a template to amplify DNA encoded with a TAT signal sequence derived from HIV and oxygen derivative degradation domain (ODD) derived from the HIF-1α gene. This was treated with the BamHI and EcoRI restriction enzymes and then integrated between BamHI and EcoRI of the pGEX-6P-3 plasmid (Amersham Pharmacia Biotech) to produce pGEX/TAT-ODD.
31) TAT-sense-BamHI Primer (SEQ ID NO: 52) aggatcctatggtcgtaagaaacgt
32) ODD-anti-EcoRI primer (SEQ ID NO: 53) agaattcctggaatactgtaactgt
Meanwhile, PCR was carried out using the following two synthetic oligo-DNAs and cDNA of the A549 cell strain derived from a human lung cancer as a template to amplify a human derived Caspase-3 gene. The gene was treated with the EcoRI and SaII restriction enzymes and integrated between EcoRI and SaII of pGEX/TAT-ODD to produce the pGEX/TAT-ODD3-0-wt.Casp3 plasmid for expressing the GST-TAT-ODD-wt.Caspase3 protein having an N terminus fused with a GST tag.
33) Casp-sense-EcoRI primer (SEQ ID NO: 54) agaattcatggagaacactgaaaac
34) Casp-anti-SaII primer (SEQ ID NO: 55) agtcgacttagtgataaaaatagag
Further, the Caspase 3 mutant (hereinafter, referred to as mut. Caspase3) having no apoptosis derivation activity was produced in accordance with the document of Vocero-Akbani, A. M., Heyden, N. V., Lissy, N. A., Ratner, L. and Dowdy, S. F. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat. Med. 5: 29-33, 1999. This structural gene was amplified by PCR using the Casp-sense-EcoRI primer and the Casp-anti-SaII primer, treated with the EcoRI and SaII restriction enzymes, and integrated between EcoRI and SaII of pGEX/TAT-ODD to produce pGEX/TAT-ODD3-0-mut.Casp3.
<2> Purification of TAT-ODD-wt./mut.Caspase3 Fused Protein
E. coli BL21 (DE3) pLysS competent cells (Novagen) were transformed by using pGEX/TAT-ODD3-0-wt.Casp3 and pGEX/TAT-ODD3-0-mut.Casp3. On the following day, a single colony was picked up from each of these culture plates, planted to 10 ml of a TB medium (containing 50 μg/ml of ampicillin) and cultured with shaking at 37° C.
On the next day, 1 ml of each overnight culture was added to 200 ml of a TB medium (containing 50 μg/ml of ampicillin) and further cultured with shaking at 37° C. When the absorbance OD600 of each culture liquid reached 0.5, IPTG was added to each culture liquid to a final concentration of 0.5 M in order to induce the expression of a fused protein, and culture was continued until the following day.
The purification of each fused protein which was expressed in large quantities was carried out in accordance with the attached protocol using the Glutathione Sepharose 4B gel (Amersham Pharmacia Biotech) and PreScission Protease (Amersham Pharmacia Biotech).
3> Study on Oxygen Concentration Dependent Apoptosis Derivation Activity
In the following operation, the NIH3T3 mouse fetal cell strain was cultured in a 5% CO2 incubator at 37° C. using a Dulbecco's MEM medium (GIBCO BRL) containing 10% of FCS, 100 U/ml of penicillin, and 100 μg/ml of streptomycin (Meiji Pharmaceuticals) as an ordinary medium.
1×105 NIH3T3 cells were scattered over a 6-hole multiwell dish, Cbz-LLL was added to well Nos. 4, 5, and 6 to a final concentration of 50 μM, and the same amount of dimethyl sulfoxide (DMSO) as Cbz-LL added to the well Nos. 4, 5, and 6 was added to well Nos. 1, 2 and 3. On the following day, each well was cleaned with serum-free D-MEM twice. A fused protein shown in Table 15 below was added to each well. Further, well Nos. 1, 2, and 3 were cultured by supplying 20% of O2 and well Nos. 4, 5, and 6 were cultured by supplying 1% of O2 for 24 hours to observe the apoptosis derivation activity depending on oxygen concentration of each fused protein.











TABLE 15







Well No.
Fused protein
Amount of protein









1, 4
Addition of only buffer
0 μg/30 μl



2, 5
TAT-ODD-mut.Casp3
7.5 μg/30 μl



3, 6
TAT-ODD-Caspase3
7.5 μg/30 μl










As a result, when TAT-ODD-wt.Caspase 3 fused protein was added and culture was carried out under hypoxic conditions, particularly strong apoptosis could be observed as shown in Table 16 (well No. 6) (indicated by +++ in Table 16). It is considered that a slight amount of apoptosis observed in well Nos. 4 and 5 was obtained by the derivation of the activity of genome-derived Caspase3 by Cbz-LLL.










TABLE 16








Apoptosis




Culture
derivation


Well No.
Added protein
conditions
activity







1
—
Aerobic
−


2
TAT-ODD-mut.Casp3
Aerobic
−


3
TAT-ODD-wt.Casp3
Aerobic
−


4
—
Hypoxic
+


5
TAT-ODD-mut.Casp3
Hypoxic
+


6
TAT-ODD-wt.Casp3
Hypoxic
+++









Further, the observation results of apoptosis in each well are shown in FIG. 9.
These results show that in a cell in which the TAT-ODD-Caspase3 fused protein is placed under aerobic conditions, fused protein is degraded while in a cell in which it is placed in hypoxic conditions, it is stabilized and activated to derive apoptosis.
INDUSTRIAL APPLICABILITY
The region which takes part in the stabilization of the HIF-1α protein can be identified by the present invention.
There can be provided a fused protein which comprises a protein having a region taking part in the stabilization of the specified HIF-1α protein and has stability dependent on oxygen conditions in a cell.
There can be also provided a fused protein which comprises a protein having a region taking part in the stabilization of the specified HIF-1α protein and has protein transduction activity through cell membrane and stability dependent on oxygen conditions in a cell.
Since the existence of a desired protein can be adjusted according to the amount of oxygen in a cell harboring a fused protein by the present invention, the present invention can be used for the detection of a cell under hypoxic conditions and the hindrance of the growth of a cell under hypoxic conditions.

## Claims

1. An isolated polynucleotide encoding a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

2. The polynucleotide of claim 1 consisting of SEQ ID NO: 2.

3. A method of controlling the presence of a protein in a cell harboring a gene of interest (GOI) encoding a protein of interest (POI), comprising:
expressing the fused POI comprising a nuclear localization signal, a polypeptide (A) or (B), and a POI, when the GOI encoding the POI is inserted between a polynucleotide encoding the polypeptide (A) or (B), and the polynucleotide encoding the nuclear localization signal, wherein said polypeptide (A) or (B) is:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or
(B) a polypeptide having an amino acid sequence comprising at least 16 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 1,
wherein the polypeptide (B) imparts stability dependent on an oxygen concentration to the fused POI.

4. The method according to claim 3, wherein the fused POI is controlled such that it exists in a cell under hypoxic conditions and does not exist under aerobic conditions.

5. A fusion protein comprising:
a polypeptide (A) or (B1);
a polypeptide (C) or (D) having a TAT signal sequence (TAT) from HIV; and
a protein of interest (POI), wherein the fusion protein has transduction activity through a cell membrane and stability dependent on an oxygen concentration in a cell, wherein polypeptide (A) or (B1) is:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1;
(B1) a polypeptide consisting of whole or part of contiguous amino acid residues 24 to 79 of SEQ ID NO: 39, said polypeptide comprising an amino acid sequence consisting of at least 16 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 1, wherein said polypeptide imparts stability dependent on an oxygen concentration to said POI, when said POI is fused to a fusion protein comprising polypeptide (B1) and said polypeptide of TAT to form a fused POI;


and wherein (C) or (D) is:
(C) a polypeptide having the amino acid sequence of SEQ ID NO: 4; or
(D) a polypeptide having an amino acid sequence comprising at least 9 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through a membrane to the fusion protein.

6. The fusion protein of claim 5, wherein said fusion protein exists more stably in a cell under hypoxic conditions than under aerobic conditions.

7. The fusion protein of claim 5, wherein said POI is a labeling protein or a cytotoxic protein.

8. A method of controlling the presence of a fusion protein in a cell, comprising:
transducing the fusion protein of claim 5 into a cell from outside of the cell; and
controlling the stability of the fusion protein according to an oxygen concentration in the transduced cell.

9. The method of claim 8, wherein the fusion protein is more stable in a cell under hypoxic conditions than under aerobic conditions.

10. A fusion protein comprising:
a nuclear localization signal;
a polypeptide having protein transduction activity through a cell membrane;
a protein of interest (POI); and
a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1,
wherein the fusion protein has protein transduction activity through a cell membrane and stability dependent on an oxygen concentration in a cell.

11. The fusion protein of claim 10, wherein the polypeptide having protein transduction activity through a cell membrane is a TAT signal sequence from HIV, (C) or (D) and wherein (C) or (D) is:
(C) a polypeptide having the amino acid sequence of SEQ ID NO: 4;
(D) a polypeptide having an amino acid sequence comprising at least 9 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through a membrane to the fusion protein.

12. The fusion protein of claim 10, wherein said fusion protein exists more stably in a cell under hypoxic conditions than under aerobic conditions.

13. The fusion protein of claim 10, wherein said POI is a labeling protein or a cytotoxic protein.

14. A method of controlling the presence of a fusion protein in a cell, comprising:
transducing the fusion protein of claim 10 into a cell from outside of the cell; and
controlling stability of the fusion protein according to an oxygen concentration in the transduced cell.

15. The method of claim 14, wherein the fusion protein is more stable in a cell under hypoxic conditions than under aerobic conditions.

16. A vector comprising a polynucleotide encoding a polypeptide having the amino acid sequence of SEQ ID NO: 1 and further comprising, a polynucleotide encoding a nuclear localization signal, wherein the vector is capable of expressing a fusion protein comprising the nuclear localization signal, the polypeptide having the amino acid sequence of SEQ ID NO: 1, and a protein of interest (POI), wherein a gene of interest (GOI) encoding the POI is inserted between the polynucleotide encoding the polypeptide having the amino acid sequence of SEQ ID NO: 1, and the polynucleotide encoding the nuclear localization signal.

17. A cell comprising the vector of claim 16.

18. The cell of claim 17, wherein said cell is a microorganism.

19. The cell of claim 18, wherein said microorganism is Escherichia coli.

20. The vector of claim 16 wherein the GOI is operably fused to said polynucleotide encoding the polypeptide having the amino acid sequence of SEQ ID NO: 1, and the polynucleotide encoding the nuclear localization signal.

21. The vector of claim 20 wherein the fused POI is unstable under aerobic conditions.

22. The vector of claim 20, wherein the POI is a labeling protein or a cytotoxic protein.

23. A method of controlling an amount of a protein of interest (POI) in a cell, comprising:
introducing the vector of claim 20 into the cell;
subjecting the cell to more hypoxic or more aerobic conditions; and
expressing the fusion protein from the vector, wherein the amount of POI in the fusion protein is higher under the more hypoxic conditions than under the more aerobic conditions.

24. A method of inhibiting growth of a cell under hypoxic conditions, comprising:
introducing the vector of claim 20 into the cell, in which said POI is a cytotoxic protein; and
expressing the fused POI encoded by the vector in the cell under hypoxic conditions.

25. A method of detecting a cell which is under hypoxic conditions, comprising:
introducing the vector of claim 20 into a cell;
expressing the fusion protein from the vector; and
determining an amount of the POI in the fusion protein in the cell, wherein the amount of said POI determined being significantly greater than an amount observed under aerobic conditions indicates that the cell is under hypoxic conditions.

26. The method of claim 25, wherein the POI is a labeling protein.

27. A vector, which comprises:
a polynucleotide encoding a nuclear localization signal; and
a polynucleotide encoding a polypeptide (A) or (B); wherein said polypeptide (A) or (B), comprises:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or
(B) a polypeptide consisting of whole or part of contiguous amino acid residues 24 to 79 of SEQ ID NO: 39, said polypeptide comprising an amino acid sequence consisting of at least 16 contiguous acid residues in the amino acid sequence of SEQ ID NO: 1, wherein said polypeptide (B) imparts stability dependent on an oxygen concentration to a polypeptide of interest (POI), when said POI is fused to a fusion protein comprising polypeptide (B) and said nuclear localization signal to form a fused POI, and wherein said vector is capable of expressing a fusion protein comprising the nuclear localization signal, the polypeptide (A) or (B), and a POI, when a gene of interest (GOI) encoding the POI is inserted between the polynucleotide encoding the nuclear localization signal, and the polynucleotide encoding the polypeptide (A) or (B).

28. The vector of claim 27, wherein the fusion protein exists more stably in a cell under hypoxic conditions than under aerobic conditions.

29. The vector of claim 27, wherein the polynucleotide encoding the polypeptide (A) or (B) has the nucleotide sequence consisting of whole or a part of contiguous nucleotides 71 to 246 of SEQ ID NO: 38, said polynucleotide encoding an amino acid sequence consisting of at least 16 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 1.

30. The vector of claim 27, wherein the polynucleotide encoding the polypeptide (C) or (D) has the nucleotide sequence of SEQ ID NO: 5 or part thereof, said polynucleotide encoding at least 9 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 4.

31. The vector of claim 27, which further comprises the GOI encoding a protein of interest (POI).

32. The vector of claim 31, wherein the POI is a labeling protein or a cytotoxic protein.

33. A method of inhibiting growth of a cell under hypoxic conditions, comprising:
introducing the vector of claim 31 into the cell in which said POI is a cytotoxic protein; and
expressing the fused POI encoded by the vector in the cell under hypoxic conditions.

34. A method of detecting a cell, which is under hypoxic conditions, comprising:
introducing the vector of claim 31 into a cell,
expressing the fusion protein from the vector, and
determining an amount of the POI in the fusion protein in the cell, wherein the amount of said POI determined being significantly greater than an amount observed under aerobic conditions indicates that the cell is under hypoxic conditions.

35. The method of claim 34, wherein the POI is a labeling protein.

36. The vector of claim 27, which further comprises a polypeptide having protein transduction activity through a membrane.

37. The vector of claim 36, wherein the polypeptide having protein transduction activity through a cell membrane is a TAT signal sequence from HIV comprising (C) or (D), and wherein (C) or (D) is:
(C) a polypeptide having the amino acid sequence of SEQ ID NO: 4; or
(D) a polypeptide having an amino acid sequence comprising at least 9 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through a membrane to the fusion protein.

38. The vector of claim 36, which further comprises a GOI encoding a protein of interest (POI).

39. The vector of claim 38, wherein the protein of interest (POI) is a labeling protein or a cytotoxic protein.

40. A method of detecting a cell, which is under hypoxic conditions, comprising:
introducing the vector of claim 38 into a cell,
expressing the fusion protein from the vector, and
determining an amount of the POI in the fusion protein in the cell, wherein the amount of said POI determined being significantly greater than an amount observed under aerobic conditions indicates that the cell is under hypoxic conditions.

41. The method of claim 40, wherein the POI is a labeling protein.

42. A vector which comprises:
a polynucleotide encoding a polypeptide (A) or (B1); and
a polynucleotide encoding a polypeptide (C) or (D) having a TAT signal sequence (TAT) from HIV,

wherein said polypeptide (A) or (B1) is:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1; or
(B1) a polypeptide consisting of whole or part of contiguous amino acid residues 24 to 79 of SEQ ID NO: 39, said polypeptide comprising an amino acid sequence consisting of at least 16 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 1, wherein said polypeptide imparts stability dependent on an oxygen concentration to a protein of interest (POI) when said POI is fused to a fusion protein comprising polypeptide (A) or (B1) and said polypeptide TAT to form a fused POI,

and wherein (C) or (D) is:
(C) a polypeptide having the amino acid sequence of SEQ ID NO: 4; or
(D) a polypeptide having an amino acid sequence comprising at least 9 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 4 and imparting protein transduction activity through a membrane to the fusion protein and wherein said vector is capable of expressing a fusion protein comprising the polypeptide (C) or (D), the polypeptide (A) or (B1), and a POI when a gene of interest (GOI) encoding the POI is inserted between the polynucleotide encoding the polypeptide (C) or (D), and the polynucleotide encoding the polypeptide (A) or (B1).

43. The vector of claim 42, wherein the fusion protein exists more stably in a cell under hypoxic conditions than under aerobic conditions.

44. The vector of claim 42, wherein the polynucleotide encoding the polypeptide (A) or (B1) has the nucleotide sequence consisting of whole or a part of contiguous nucleotides 71 to 246 of SEQ ID NO: 38, said polynucleotide encoding an amino acid sequence consisting of at least 16 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 1.

45. The vector of claim 42, wherein the polynucleotide encoding the polypeptide (C) or (D) has the nucleotide sequence of SEQ ID NO: 5 or part thereof, said polynucleotide encoding at least 9 contiguous amino acid residues in the amino acid sequence of SEQ ID NO: 4.

46. The vector of claim 42, which further comprises the gene of interest (GOI) encoding a protein of interest (POI).

47. The vector of claim 46, wherein the protein of interest (POI) is a labeling protein or a cytotoxic protein.